HC Wainwright restated their buy rating on shares of ChromaDex (NASDAQ:CDXC – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $11.00 target price ...
Stock analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of OPKO Health in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst Y.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results